TARO PHARMACEUTICAL INDUSTRIES LTD
taro.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Jun 29, 2023. Its latest SEC filing is a 15F-12B from Jul 5, 2024.
20-F for FY2023, filed Jun 29, 2023
The sections below describe the company as of the FY2023 annual report.
Who Were Their Customers?
In the U.S., Israel, and Canada, sales mainly come through Taro's own sales force; elsewhere, agents and distributors sell its products. U.S. buyers include wholesalers and retail chains, institutions, and individual consumers.
20-F for FY2023, filed Jun 29, 2023In the U.S., Israel and Canada, our sales are primarily generated by our own dedicated sales force. In other countries, we sell through…View ↗
In the year ended March 31, 2023, revenue in the U.S. accounted for 63% of total consolidated net sales. In addition to marketing Rx drugs…View ↗
In the year ended March 31, 2023, sales in Israel accounted for less than 8% of our total consolidated net sales. The marketing, sales, and…View ↗
20-F for FY2023, filed Jun 29, 2023
For the year ended March 31, 2023, the Company had net sales to two different U.S. customers of 8.8% and 8.7% of consolidated net sales.…View ↗
How Were They Changing?
Added a skin-care business
The latest business includes Alchemee and its Proactiv skin-care products, adding an over-the-counter dermatology business to the earlier portfolio.
20-F for FY2020, filed Jun 19, 2020 20-F for FY2023, filed Jun 29, 2023We operate principally through three entities: Taro Israel, and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc.…View ↗
Loading...
